CA-ATTACKIQ
13.4.2021 09:02:09 CEST | Business Wire | Press release
AttackIQ ®, the leading independent vendor of Breach and Attack Simulation (BAS) systems, today announced that Ross Brewer has been promoted to General Manager and Vice President of Europe, Middle East and Africa (EMEA) and Asia Pacific Japan (APJ) regions. In his new role, Brewer will be responsible for developing the strategy to expand AttackIQ’s presence in the regions, including delivering IT security and risk management leaders with solutions to identify gaps in their security posture more effectively and prioritize security initiatives more efficiently.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210413005210/en/
Brewer brings more than 35 years of sales and management experience with technology organizations across the globe. He previously served as strategic advisor for EMEA at AttackIQ, where he played a pivotal role in shaping the messaging and selling strategies over the last year to deliver strong growth in the financial and insurance services, oil and gas, healthcare, government, higher education, and technology sectors.
Additionally, he helped launch AttackIQ’s Academy in EMEA and APJ to provide advanced cybersecurity training, modularized curriculum, and cyberrange labs to security practitioners free of charge, in these markets. Today, more than 9,000 students in 100 countries across EMEA and APJ are continuing their cybersecurity education with AttackIQ Academy.
“CISOs around the globe recognize the importance of being adequately prepared for breaches, as the cost, complexity and frequency of cybersecurity attacks continues to exponentially increase,” said Carl Wright, Chief Commercial Officer, AttackIQ. “Ross has a proven track record of helping organizations in EMEA and APJ invest strategically in cybersecurity technology, partnerships, and practice enablement. We look forward to continuing to help security and risk leaders validate their investments and gain confidence with a threat-informed defense.”
In addition to large private and public customers throughout EMEA and APJ, including Bupa, BT, and a number of Government Ministries including Finance, Energy, Health and Sovereign Investment funds, AttackIQ has seen significant growth in the Gulf Cooperation Council (GCC) region as governments in countries like The United Arab Emirates, Kingdom of Saudi Arabia, Qatar, Oman, Kuwait and Bahrain look for cybersecurity solutions to protect their digital transformation initiatives.
As part of AttackIQ’s strategic expansion in these regions, the company signed a distribution agreement in November 2020 with Westcon-Comstor, a leading global technology distributor in the EMEA and APAC regions. Today, AttackIQ is building a presence and teams in the United Kingdom, United Arab Emirates, and Kingdom of Saudi Arabia.
“AttackIQ’s strong international growth is a direct result of its industry-leading platform, and I am excited to be joining the executive management team to continue helping organizations in these regions drive toward cybersecurity excellence,” said Brewer. “As recently noted by Gartner , breach and attack simulation is in the list of top security and risk management trends of 2021 due to its ability to help proactively identify and resolve gaps in security postures. The acceleration of c-suite leaders adopting a threat-informed defense and purple team construct with the help of AttackIQ is a direct result of leaders needing a higher level of confidence in their defensive posture.”
About AttackIQ
AttackIQ, the leading independent vendor of breach and attack simulation solutions, built the industry’s first Security Optimization Platform for continuous security control validation and improving security program effectiveness and efficiency. AttackIQ is trusted by leading organizations worldwide to plan security improvements and verify that cyberdefenses work as expected, aligned with the MITRE ATT&CK framework. The Company is committed to giving back to the cybersecurity community through its free AttackIQ Academy , open Preactive Security Exchange, and partnership with the MITRE Engenuity . For more information, visit www.attackiq.com . Follow AttackIQ on Twitter , Facebook , LinkedIn , and YouTube .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005210/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom